|
1
|
Hess LM and Stehman FB: State of the
science in ovarian cancer quality of life research: A systematic
review. Int J Gynecol Cancer. 22:1273–1280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rooth C: Ovarian cancer: Risk factors,
treatment and management. Br J Nurs. 22(Suppl): S23–S30. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hua KT, Wang MY, Chen MW, Wei LH, Chen CK,
Ko CH, Jeng YM, Sung PL, Jan YH, Hsiao M, et al: The H3K9
meth-yltransferase G9a is a marker of aggressive ovarian cancer
that promotes peritoneal metastasis. Mol Cancer. 13:1892014.
View Article : Google Scholar
|
|
5
|
Naora H and Montell DJ: Ovarian cancer
metastasis: Integrating insights from disparate model organisms.
Nat Rev Cancer. 5:355–366. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: Biology, endocrinology and
pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
|
|
7
|
Imai T, Horiuchi A, Wang C, Oka K, Ohira
S, Nikaido T and Konishi I: Hypoxia attenuates the expression of
E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells.
Am J Pathol. 163:1437–1447. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peters LL, Weier HU, Walensky LD, Snyder
SH, Parra M, Mohandas N and Conboy JG: Four paralogous protein 4.1
genes map to distinct chromosomes in mouse and human. Genomics.
54:348–350. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conboy J, Kan YW, Shohet SB and Mohandas
N: Molecular cloning of protein 4.1, a major structural element of
the human erythrocyte membrane skeleton. Proc Natl Acad Sci USA.
83:9512–9516. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parra M, Gascard P, Walensky LD, Gimm JA,
Blackshaw S, Chan N, Takakuwa Y, Berger T, Lee G, Chasis JA, et al:
Molecular and functional characterization of protein 4.1B, a novel
member of the protein 4.1 family with high level, focal expression
in brain. J Biol Chem. 275:3247–3255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Walensky LD, Blackshaw S, Liao D, Watkins
CC, Weier HU, Parra M, Huganir RL, Conboy JG, Mohandas N and Snyder
SH: A novel neuron-enriched homolog of the erythrocyte membrane
cytoskeletal protein 4.1. J Neurosci. 19:6457–6467. 1999.PubMed/NCBI
|
|
12
|
Wang H, Liu C, Debnath G, Baines AJ,
Conboy JG, Mohandas N and An X: Comprehensive characterization of
expression patterns of protein 4.1 family members in mouse adrenal
gland: Implications for functions. Histochem Cell Biol.
134:411–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun CX, Robb VA and Gutmann DH: Protein
4.1 tumor suppressors: Getting a FERM grip on growth regulation. J
Cell Sci. 115:3991–4000. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dafou D, Grun B, Sinclair J, Lawrenson K,
Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM,
Al-Attar A, et al: Microcell-mediated chromosome transfer
identifies EPB41L3 as a functional suppressor of epithelial ovarian
cancers. Neoplasia. 12:579–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong SY, Haack H, Kissil JL, Barry M,
Bronson RT, Shen SS, Whittaker CA, Crowley D and Hynes RO: Protein
4.1B suppresses prostate cancer progression and metastasis. Proc
Natl Acad Sci U S A. 104:12784–12789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Robb VA, Li W, Gascard P, Perry A,
Mohandas N and Gutmann DH: Identification of a third protein 4.1
tumor suppressor, protein 4.1R, in meningioma pathogenesis.
Neurobiol Dis. 13:191–202. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xi C, Ren C, Hu A, Lin J, Yao Q, Wang Y,
Gao Z, An X and Liu C: Defective expression of protein 4.1N is
correlated to tumor progression, aggressive behaviors and
chemotherapy resistance in epithelial ovarian cancer. Gynecol
Oncol. 131:764–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pouysségur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakayama K, Kanzaki A, Hata K, Katabuchi
H, Okamura H, Miyazaki K, Fukumoto M and Takebayashi Y:
Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in
human ovarian carcinoma. Cancer Lett. 176:215–223. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Semenza GL: Oxygen sensing, homeostasis
and disease. N Engl J Med. 365:537–547. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao D and Johnson RS: Hypoxia: A key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee K, Zhang H, Qian DZ, Rey S, Liu JO and
Semenza GL: Acriflavine inhibits HIF-1 dimerization, tumor growth
and vascularization. Proc Natl Acad Sci U S A. 106:17910–17915.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo W, Hu H, Chang R, Zhong J, Knabel M,
O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is
a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell.
145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moeller BJ, Richardson RA and Dewhirst MW:
Hypoxia and radiotherapy: Opportunities for improved outcomes in
cancer treatment. Cancer Metastasis Rev. 26:241–248. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Esteban MA, Tran MG, Harten SK, Hill P,
Castellanos MC, Chandra A, Raval R, O'brien TS and Maxwell PH:
Regulation of E-cadherin expression by VHL and hypoxia-inducible
factor. Cancer Res. 66:3567–3575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krishnamachary B, Zagzag D, Nagasawa H,
Rainey K, Okuyama H, Baek JH and Semenza GL: Hypoxia-inducible
factor-1-dependent repression of E-cadherin in von hippel-lindau
tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A
and ZFHX1B. Cancer Res. 66:2725–2731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mak P, Leav I, Pursell B, Bae D, Yang X,
Taglienti CA, Gouvin LM, Sharma VM and Mercurio AM: ERbeta impedes
prostate cancer EMT by destabilizing HIF-1alpha and inhibiting
VEGF-mediated snail nuclear localization: Implications for gleason
grading. Cancer Cell. 17:319–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Ann Rev
Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar
|
|
30
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Evans AJ, Russell RC, Roche O, Burry TN,
Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, et
al: VHL promotes E2 box-dependent E-cadherin transcription by
HIF-mediated regulation of SIP1 and snail. Mol Cell Biol.
27:157–169. 2007. View Article : Google Scholar :
|
|
33
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by
HIF-1alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pouyssegur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bernkopf DB and Williams ED: Potential
role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of
advanced prostate cancer. Expert Opin Ther Targets. 12:845–853.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joshi HP, Subramanian IV, Schnettler EK,
Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy
S, Zeng Y, Shah VH, Sood AK and Ramakrishnan S: Dynamin 2 along
with microRNA-199a reciprocally regulate hypoxia-inducible factors
and ovarian cancer metastasis. Proc Natl Acad Sci USA.
111:5331–5336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Milosevic M, Warde P, Ménard C, Chung P,
Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M,
et al: Tumor hypoxia predicts biochemical failure following
radiotherapy for clinically localized prostate cancer. Clin Cancer
Res. 18:2108–2114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cangul H, Salnikow K, Yee H, Zagzag D,
Commes T and Costa M: Enhanced overexpression of an
HIF-1/hypoxia-related protein in cancer cells. Environ Health
Perspect. 110(Suppl 5): S783–S788. 2002. View Article : Google Scholar
|
|
39
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
40
|
Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z,
Wan Y and Di W: Hypoxia inducible factor 1α-mediated LOX expression
correlates with migration and invasion in epithelial ovarian
cancer. Int J Oncol. 42:1578–1588. 2013.PubMed/NCBI
|
|
41
|
Wong C, Wellman TL and Lounsbury KM: VEGF
and HIF-1alpha expression are increased in advanced stages of
epithelial ovarian cancer. Gynecol Oncol. 91:513–517. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Osada R, Horiuchi A, Kikuchi N, Yoshida J,
Hayashi A, Ota M, Katsuyama Y, Melillo G and Konishi I: Expression
of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha
and von hippel-lindau protein in epithelial ovarian neoplasms and
allelic loss of von hippel-lindau gene: Nuclear expression of
hypoxia-inducible factor 1alpha is an independent prognostic factor
in ovarian carcinoma. Hum Pathol. 38:1310–1320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Beavon IR: Regulation of E-cadherin: Does
hypoxia initiate the metastatic cascade? Mol Pathol. 52:179–188.
1999. View Article : Google Scholar
|
|
44
|
Tomita K, van Bokhoven A, van Leenders GJ,
Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin
switching in human prostate cancer progression. Cancer Res.
60:3650–3654. 2000.PubMed/NCBI
|
|
45
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Thomassin L, Werneck CC, Broekelmann TJ,
Gleyzal C, Hornstra IK, Mecham RP and Sommer P: The pro-regions of
lysyl oxidase and lysyl oxidase-like 1 are required for deposition
onto elastic fibers. J Biol Chem. 280:42848–42855. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and
Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in
snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pez F, Dayan F, Durivault J, Kaniewski B,
Aimond G, Le Provost GS, Deux B, Clézardin P, Sommer P, Pouysségur
J and Reynaud C: The HIF-1-inducible lysyl oxidase activates HIF-1
via the Akt pathway in a positive regulation loop and synergizes
with HIF-1 in promoting tumor cell growth. Cancer Res.
71:1647–1657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ye K, Hurt KJ, Wu FY, Fang M, Luo HR, Hong
JJ, Blackshaw S, Ferris CD and Snyder SH: Pike. A nuclear gtpase
that enhances PI3kinase activity and is regulated by protein 41N.
Cell. 103:919–930. 2000. View Article : Google Scholar
|
|
53
|
Kisseleva MV, Cao L and Majerus PW:
Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV
inhibits Akt/protein kinase B phosphorylation and leads to
apoptotic cell death. J Biol Chem. 277:6266–6272. 2002. View Article : Google Scholar
|
